Neovascular GlaucomaNCT00441181
Effects of Travoprost on Neovascular Glaucoma
A study testing Travoprost in people with Neovascular Glaucoma, run by Federal University of São Paulo at 1 site in Brazil.
Trial summary
Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neovascular Glaucoma
- What is being tested?
- Travoprost
- How many people
- 40 participants
- Where
- 1 siteBrazil
- Study dates
- Jan 2008to Dec 2008
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Neovascular glaucoma of known cause
- Older than 18 years
- Previously submitted to retinal photocoagulation
- Under medical treatment to glaucoma
Who cannot join
- Need of antiglaucomatous surgery
- Previous ocular surgery in the last 6 months
- Pregnancy
Trial locations and contacts
1 site in 1 country.
About this study
Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma.
- Conditions
- Neovascular Glaucoma
- Being tested
- Travoprost
- Keywords
- Neovascular glaucoma, Travoprost
- Medical subject headings
- Glaucoma, Neovascular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TravoprostDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraocular pressure
Secondary outcomes (1)
Inflammation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2007 (estimated)
- Study startJan 2008
- Study completionDec 2008 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neovascular GlaucomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Federal University of São Paulo
- Sponsor type
- University, hospital or other
- Investigators
- Luiz A Melo Jr, MD, Principal investigator, Federal University of São Paulo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00441181
- Sponsor's protocol ID
- UNIFESP 2007-02
- Status last verified
- Feb 2007
- First submitted
- 27 Feb 2007
- Last updated
- 22 Jun 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Travoprost on Neovascular Glaucoma
- ClinicalTrials.gov ID
- NCT00441181
- Acronym / sponsor ID
- UNIFESP 2007-02
- Conditions
- Neovascular Glaucoma
- Keywords
- Neovascular glaucoma, Travoprost
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Federal University of São PauloUniversity, hospital or other
- Study start
- Jan 2008
- Study completion
- Dec 2008 (estimated)
- First posted
- 28 Feb 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prostaglandin analogues have not been used in the treatment of neovascular glaucoma because of suspicious lack of efficacy. This study aims at assessing the effect of travoprost on neovascular glaucoma.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Neovascular glaucoma of known cause
- Older than 18 years
- Previously submitted to retinal photocoagulation
- Under medical treatment to glaucoma
Key exclusion criteria (3 listed)
- Need of antiglaucomatous surgery
- Previous ocular surgery in the last 6 months
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Travoprost | Drug | – |
Primary outcome
Intraocular pressure
1 secondary outcome
Inflammation
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2011.
Related trials for Neovascular Glaucoma
RecruitingObservational study
Observation of Iris Blood Flow Via OCTA in Diabetic Neovascular Glaucoma
Neovascular Glaucoma, Type 2 Diabetes
RecruitingObservational study
Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Neovascular Glaucoma
Active, not recruiting
Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma
Neovascular Glaucoma
Recruiting
Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT
Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression
Active, not recruitingPhase 1
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
Neovascular Glaucoma, Neovascularization
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luiz A Melo Jr, MD principal investigator
Federal University of São Paulo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Travoprost in people with Neovascular Glaucoma, run by Federal University of São Paulo at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 22 Jun 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraocular pressure. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2011.